MULTIPLE MYELOMA: A STUDY OF 24 PATIENTS TREATED WITH RADIOACTIVE ISOTOPES (P^32 AND SR^88)

Publisher Website
Google Scholar
Abstract
Possible advantages over X-ray therapy in the treatment of multiple myelomata are sought through the admn. of radioactive P and radioactive Sr. These isotopes act similarly to other penetrating radiations, but localize in rapidly growing tissue and in bone; hence seem indicated in metastatic bone tumors and in multiple myelomata. 24 patients ranging in age from 29-66 yrs. with an avg. at 51.9 yrs. were studied; 21 were treated with these isotopes. 7 of the 21 cases were not definitely benefited by treatment with p32 or Sr89 or both. 8 cases showed questionable improvement; 5 showed relatively satisfactory results, 1 showing remarkable improvement for over 5 years. Length of life after onset in patients following treatment ranged from 6 mos, to nearly 9 yrs. with avg. of 3 yrs. Dosages were individualized; courses averaged about 5-10 me over periods from 4 to 6 weeks, with p32- Sr89 dosage was highly individualized and depended on whether it accompanied p32.